Skip to main content
SpringerLink
Log in

The Future Role of Inotropic Drugs

  • Published:
Drugs Aims and scope Submit manuscript

Summary

Inotropic drugs have not, as yet, been shown in double-blind, randomised and placebo-controlled trials to be of value in the treatment of heart failure. There are theoretical reasons why inotropic drugs may initiate arrhythmias, worsen ischaemia and possibly even increase mortality.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Bayliss J, Norell MS, Canepa-Anson R, Reid C, Poole-Wilson PA, Sutton G. Clinical importance of the renin-angiotensin system in chronic heart failure: double blind comparison of captopril and prazosin. British Medical Journal 290: 1861–1865, 1985

    Article  PubMed  CAS  Google Scholar 

  • Bayliss J, Canepa-Anson R, Norell MS, Poole-Wilson PA, Sutton G. Vasodilatation with captopril and prazosin in chronic heart failure: a double blind study at rest and on exercise. British Heart Journal 55: 265–273, 1986

    Article  PubMed  CAS  Google Scholar 

  • Bigger JT, Fleiss JL, Rolnitzky LM, Meralo JP, Ferrick KJ. Effect of digitalis treatment on survival after acute myocardial infarction. American Journal of Cardiology 55: 623–630, 1985

    Article  PubMed  Google Scholar 

  • Byington R, Goldstein S. Association of digitalis therapy with mortality in survivors of acute myocardial infarction: observations in the beta-blocker heart attack trial. Journal of the American College of Cardiology 6: 976–982, 1985

    Article  PubMed  CAS  Google Scholar 

  • Currie PJ, Kelly MJ, Middlebrook K, Federman J, Sainsbury E, et al. Acute intravenous and sustained oral treatment with the beta1 agonist prenalterol in patients with chronic severe cardiac failure. British Heart Journal 51: 530–538, 1984

    Article  PubMed  CAS  Google Scholar 

  • Dawson JR, Canepa-Anson R, Kuan P, Reuben SR, Poole-Wilson PA, Sutton G. Symptoms, haemodynamics and exercise capacity during long term treatment of chronic heart failure. Experience with pirbuterol. British Heart Journal 50: 282–289, 1983

    Article  PubMed  CAS  Google Scholar 

  • Dibianco R, Shabetai R, Silverman BD, Leier CV, Benotti JR, et al. Oral amrinone for the treatment of chronic congestive heart failure: results of a multicenter randomized double-blind and placebo-controlled withdrawal study. Journal of the American College of Cardiology 4: 855–866, 1984

    Article  PubMed  CAS  Google Scholar 

  • Dobbs SM, Kenyon WI, Dobbs RJ. Maintenance digoxin after an episode of heart failure: placebo-controlled trial in outpatients. British Medical Journal 1: 749–752, 1977

    Article  PubMed  CAS  Google Scholar 

  • Fleg JL, Gottlieb SH, Lakatta EG. Is digoxin really important in treatment if compensated heart failure? A placebo-controlled crossover study in patients with sinus rhythm. American Journal of Medicine 73: 244–250, 1982

    Article  PubMed  CAS  Google Scholar 

  • Glover DR, Wathen CG, Murray RG, Petch MC, Muir AL, et al. Are the clinical benefits of oral prenalterol in ischaemic heart failure due to beta blockade? A six month randomised double-blind comparison with placebo. British Heart Journal 53: 208–215, 1985

    Article  PubMed  CAS  Google Scholar 

  • Lambertz H, Meyer J, Erbel R. Long-term haemodynamic effects of prenalterol in patients with severe congestive heart failure. Circulation 69: 298–305, 1984

    Article  PubMed  CAS  Google Scholar 

  • Lee DC-S, Johnson RA, Bingham JB, Leahy M, Dinsmore RE, et al. Heart failure in outpatients: a randomized trial of digoxin versus placebo. New England Journal of Medicine 306: 699–705, 1982

    Article  PubMed  CAS  Google Scholar 

  • Likoff MJ, Weber KT, Andrews V, Janicki JS, Sutton M St.J, et al. Amrinone in the treatment of chronic cardiac failure. Journal of the American College of Cardiology 3: 1282–1290, 1984

    Article  PubMed  CAS  Google Scholar 

  • Lipkin DP, Poole-Wilson PA. Treatment of chronic heart failure: a review of recent drug trials. British Medical Journal 291: 993–996, 1985

    Article  PubMed  CAS  Google Scholar 

  • Madsen EB, Gilpin E, Henning H, Ahnve S, LeWinter M, et al. Prognostic importance of digitalis after acute myocardial infarction. Journal of the American College of Cardiology 3: 681–689, 1984

    Article  PubMed  CAS  Google Scholar 

  • McHaffie D, Purcell H, Mitchell-Heggs P, Guz A. The clinical value of digoxin in patients with heart failure and sinus rhythm. Quarterly Journal of Medicine 47: 401–419, 1978

    PubMed  CAS  Google Scholar 

  • Moss AJ, Davis HT, Conrad DL, DeCamilla JJ, Odoroff CL. Digitalis-associated cardiac mortality after myocardial infarction. Circulation 64: 1150–1156, 1981

    Article  PubMed  CAS  Google Scholar 

  • Muller JE, Tun ZG, Stone PH, Rude RE, Raabe DS, et al. Digoxin therapy and mortality after myocardial infarction: experience in the MILIS study. New England Journal of Medicine 314: 265–271, 1986

    Article  PubMed  CAS  Google Scholar 

  • Packer M. Vasodilator and inotropic therapy for severe chronic heart failure: passion and skepticism. Journal of the American College of Cardiologists 2: 841–852, 1983

    Article  CAS  Google Scholar 

  • Packer M, Medina N, Yushak M. Hemodynamic and clinical limitations of longterm inotropic therapy with amrinone in patients with severe chronic heart failure. Circulation 70: 1038–1047, 1984

    Article  PubMed  CAS  Google Scholar 

  • Poole-Wilson PA. The role of digitalis in the future. British Journal of Clinical Pharmacology 18: 151S–156S, 1984

    Article  PubMed  Google Scholar 

  • Roubin GS, Choong CYP, Devenish-Meares S, Sadick NN, Fletcher PJ, et al. β-adrenergic stimulation of the failing ventricle: a double-blind, randomized trial of sustained oral therapy with prenalterol. Circulation 69: 955–962, 1984

    Article  PubMed  CAS  Google Scholar 

  • Ryan TJ, Bailey KR, McCabe CH, Luk S, Fisher LD, et al. The effects of digitalis on survival in high-risk patients with coronary artery disease. Circulation 67: 735–742, 1983

    Article  PubMed  CAS  Google Scholar 

  • Wade OL, Bishop JM. Cardiac output and regional blood flow. Blackwell, 1962

  • Weber KT, Andrews V, Janicki JS. Cardiotonic agents in the management of chronic cardiac failure. American Heart Journal 103: 639–649, 1982

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Cardiothoracic Institute and National Heart Hospital, British Postgraduate Medical Federation, University of London, 2 Beaumont St, London, W1N 2DX, England

    P. A. Poole-Wilson

Authors
  1. P. A. Poole-Wilson
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Poole-Wilson, P.A. The Future Role of Inotropic Drugs. Drugs 32 (Suppl 5), 27–32 (1986). https://doi.org/10.2165/00003495-198600325-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-198600325-00004

Search

Navigation